For example, METTL3-mediated m6A modification physiologically promotes activation of dendritic cell (DC) and DC-based T cell responses [19], and loss of YTHDF1 enhances CD8+ T cell tumor infiltration, making anti-PD-L1 therapy more effective [20]. Here, CD8A is linked to neoplasm.